Focus Taiwan App
Download

Report raises doubts about UBI vaccine efficacy against COVID variants

08/30/2021 03:35 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

An expert review report released by the Food and Drug Administration (FDA) Monday raised doubts as to whether the vaccine developed by Taiwan-based United Biomedical Inc. (UBI) Asia offers sufficient protection against COVID-19 variants.


(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.
    172.30.142.80